To the Editor: The results of the Celecoxib
Long-term Arthritis Safety Study (CLASS)1
support the hypothesis that celecoxib alone does not induce anatomical lesions
in the gastrointestinal (GI) tract.
However, in the subgroup of patients who were receiving aspirin for
cardiovascular disease there was no difference in nonsteroidal anti-inflammatory
drug (NSAID)–induced GI complications between celecoxib and aspirin
vs conventional ibuprofen or diclofenac and aspirin. Because cyclooxygenase
(COX)-1 is responsible for GI integrity under physiological conditions and
because COX-2–specific inhibitors alone do not cause anatomical lesions,
we would have expected a lower rate of ulcer complications in the group receiving
celecoxib and aspirin. As outlined in the accompanying Editorial by Drs Lichtenstein
and Wolfe,2 a possible explanation for this
surprising finding might be a type II error due to the small sample size.
However, the small numerical difference observed between the 2 groups suggests
that even a statistically significant result in a study with a much larger
sample size would translate into questionable clinical benefit. Alternatively,
healing of aspirin-induced anatomical lesions, which normally involves COX-2
induction, might be delayed by celecoxib.3
In the CLASS trial, there was no washout period, and many patients were receiving
NSAIDs at baseline. Therefore, many of these patients were at risk for asymptomatic
NSAID-induced gastropathy at the time they entered the study. Thus, although
COX-2–specific inhibitors are not specifically ulcerogenic, they may
interfere with repair of NSAID-induced gastropathy.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.